"CENTOGENE unlocks the power of genetic insights to improve the quality of life of patients with genetic rare diseases. We achieve this through knowledge created by our worldwide diagnostic testing services incorporating global diversity, the world’s leading proprietary human genetic interpretation database, CentoMD® and solutions for pharmaceutical companies developing life-changing orphan drugs. As one of the most diversified and largest genetic testing companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients and their families."

During the past decade, Centogene AG conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centogene AG" are "Hepatomegaly" (3 trials), "Splenomegaly" (3 trials), "Developmental Delay" (2 trials), "Hepato-splenomegaly" (2 trials) and "Macroglossia" (2 trials). Many other conditions were trialed in "Centogene AG" in a lesser frequency.

The vast majority of trials in "Centogene AG" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Centogene AG". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Centogene AG, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centogene AG, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".